Latin American Journal of Pharmacy
(formerly *Acta Farmacéutica Bonaerense*)

Lat. Am. J. Pharm. **42** (11): (2023)

Progress In Nano Micelles Drug Delivery Recently

Mr. Akashdeep Udmale*[1], Dr. Vipulkumar Patel[1]
Department of Pharmaceutics, SRES, Sanjivani College of Pharmaceutical Education & Research, Kopargaon, Maharashtra, India-423603

Abstract:
Colloidal dispersions known as nanomicelles are made up of self-assembling nanoparticles. These nanomicelles, which, have special qualities and traits because of their size, solubility, specialised surface, and exposure to the environment. They are multifunctional as a result, which makes them essential in biological applications and many other sectors. This review focuses on the unique characteristics of nanomicelles that make them stand out from other particles and emphasise and the variety of biological applications for which they are suitable. It also focuses on the ability of nanomicelles to encapsulate substances, as well as the benefits and drawbacks of various medication loading and delivery methods. It is still exceedingly difficult to deliver therapeutic medications efficiently and specifically to target locations in., superior to successfully encapsulate medicines within. These nanomicelles are created in aqueous conditions to form orderly. The components have an impact on the size and shape of nanomicelles. it is possible to accomplish selective drug delivery. This study gives a general overview of the newly created micellar nanocarriers with various designs, emphasising their unique qualities and the guiding principles that allow for targeted and long-lasting drug administration.

Keywords: Progress, Current status, Nano micelles, Particulate, DDS.

Introduction

With micelles are colloidal structures. They are made up of molecules with various water-affinity regions. At particular temperatures and concentrations, these molecules unite to create micelles.[1-3] Micelles do not form and only exist as individual monomers below this temperature. The quantity of monomer molecules that make up As the hydrophobic parts of the micelles are protected from the aqueous environment, less free energy is available, which leads to the creation of micelles. Micelles are frequently used in medication. [4-5]

Due to their better solubility and increased intestinal permeability, polymeric micelles made of amphiphilic block copolymers are frequently utilised in therapeutics. They are useful for tumour targeting due to their extended circulation properties and high tumour accumulation. Polymeric micelles have higher levels of drug accumulation at the target site than surfactant micelles because they are Similar to viruses and lipoproteins, micelles have a restricted size range that is critical to when the increased. [6]

Makes it difficult to treat patients effectively and frequently leads to side effects. cancerous tissues, resulting in a number of negative side effects include nausea, hair loss, neuropathy, neutropenia, and kidney failure. By delivering more of the medicine to the targeted damaged tissue and reducing drug concentration at undesirable areas, nanocarriers that form complexes with pharmaceuticals offer a highly selective and specific strategy. Doxil (liposomal doxorubicin), one of many liposomal anticancer medication formulations, has already received approval. In comparison to the free medication, liposomal formulations offer benefits like improved efficacy and decreased cardiotoxicity.[7-9]

The ability of nanomicellar pharmaceuticals to overcome drug resistance has also been noted. This is because they increase by achieving concentrations via . Nanomicelles are one of the many nanotechnology important and fighting drug resistance. [10]

Compared to alternative drug delivery mechanisms like liposomes and nanotubes, nanomicelles have a number of advantages. Because of their tiny size and better drug loading capacity, they can penetrate deeply into tumour tissues and provide effective therapeutic potency. [11]

Nanomicelle-based targeted medication delivery promotes better tissue penetration and boosts drug bioavailability. When put in a polar solvent, regular micelles have an external hydrophilic portion and an inside hydrophobic core. On the other hand, reverse micelles have the hydrophobic sections facing outward and the hydrophilic parts facing inside. They are used to distribute hydrophilic medicines, proteins, and solutes and to encapsulate such substances.[12-16] illnesses, and chronic disorders, sustained medication release is crucial. Prodrug synthesis, novel polymer use, Micelles are preferable to bigger systems for focused medication delivery due to their small size. [17-19] Amphiphilic molecules can form aggregates that are stable and easy to sterilise while also increasing the solubility of sparingly soluble chemicals. The hydrophilic outer layer of micelles shields detection and capture by the resulting the hydrophobic core of micelles houses lipophilic molecules bound together by van der Waals forces. This characteristic can also be used to achieve active targeting through conjugation with a ligand.[20-22]

Amphiphilic molecules must self-assemble in aqueous media in order to create nanomicelles. Both polar (hydrophilic) and non-polar (hydrophobic) components can be found in amphiphilic compounds. regular micelles are created when the hydrophobic portion faces to form faces the solvent to form the exterior. Conversely, reverse micelles have the opposite orientation.[23-25] Surface-active substances like synthetic block copolymers and surfactants can be used to create nanomicelles. Ionic, non-ionic, and zwitterion are all possible forms for amphiphilic monomers.[26]

Preparation of Polymeric Micelles

Depending characteristics different nanomicelles prepared in different ways. are two methods frequently employed to prepare nanomicelles. Moderately hydrophobic block copolymers self-assemble into nanomicelles when using the direct dissolution method. [27-30] In this procedure, sometimes referred to as the simple equilibrium method, the medication and copolymer are dissolved in an appropriate amount of water. The creation of nanomicelles is then triggered by heating the solution. The production of the nanomicelles is caused by the dehydration of the nanomicelles' core during the heating process. Oil in water (o/w) emulsion, solution casting, and dialysis are the three subcategories of the solvent casting method.[31] Producing nanomicelles from non-water soluble copolymers is easy with dialysis. In this method, organic solvents with high boiling points that are miscible with water are used to dissolve the drug and copolymer. Copolymer and medication solution is typically longer than 12 hours. Drug-loaded nanomicelles begin to develop as the organic solvent slowly evaporates during dialysis. [32-35] But this approach might have drawbacks including ineffective encapsulation and possible medication loss. The physical entrapment of components is a step in the o/w emulsion process. In a non-miscible organic solvent with a small amount of water, the drug and polymer are dissolved. The medication is then physically trapped in the centre of the nanomicelles as a result of the solvent being evaporated. used in the solution casting process. A translucent solution is produced once the medication and polymers are dissolved in an organic solvent.[36] Depending on the features of the copolymers and the required qualities of the nanomicelles, these various preparation techniques offer flexibility.[37]

Biodistribution

Using micellar carriers tries to increase a drug's solubility and lengthen the time it spends in the bloodstream, improving targetability and therapeutic advantages. The lengthy circulation duration is influenced by metabolism and biodistribution. [38-40] In vivo biodistribution still affects the physicochemical characteristics even though the absorption phase is frequently disregarded because micelles are typically administered intravenously. Due to their small surface area, spherical micelles with a size of around 3-5 nm are often ejected by the kidneys instead of being taken up by macrophages. Small particle sizes make it simple to enter the extravascular extracellular space (EES) and pass through constricted endothelial junctions. [41] Due to their small size, polymeric nanomicelles have the benefit of the increased permeability and retention (EPR) effect. [42-43] They take advantage of inadequate lymphatic drainage to endothelium collect, and release their payload there. Even stable, 80 nm-sized polymeric micelles containing curcumin that were created using mPEG-HPMA-Bz may not fully exploit the benefits of the EPR effect. Other curcumin formulations, such as low-density lipoprotein have also shown this behaviour. Drug molecules' inherent characteristics as well as aromatic groups (like with PTX) can have an impact on how well they work.[44-45] Size, shape, and surface charge are only a few examples of the variables that greatly affect micelle biodistribution. Because the RES interacts more frequently with negatively charged cell membranes, positively charged micelles are easily absorbed by the RES.

[46-49] Negatively charged micelles, on the other hand, increase blood circulation time and reduce cellular absorption rates. When mice were used to examine the pharmacokinetics of neutral and negatively respectively, both displayed comparable blood clearance kinetics. However, anionic micelles had a roughly than neutral micelles did. The effect of the core on biodistribution varies greatly depending on the stability and content of the core.[50-53] For instance, a substantial reduction in clearance was seen The stabilisation of the micelles and decreased uptake by the liver may be attributable to the inclusion of hydrophobic lamella, which may improve hydrophobic contacts in the core.[54-55]

Applications Of Nanomicelles In Drug Delivery

As they provide nanoscale drug delivery systems, liposomes and polymeric micelles are regarded as essential tools for the treatment of cancer. These strategies seek to increase the effectiveness of delivered anticancer medications by achieving proper drug transmission time, concentration in tumours, and minimised accumulation in healthy organs and tissues. [56-58] However, the emergence of drug resistance and inadequate targeting skills have restricted the use of liposomes and lipid-based drug delivery systems. In order to get over these restrictions, Kataoka's team developed micelles that were loaded with doxorubicin (DOX) as drug delivery vehicles in the early 1990s. [59-60] In both clinical and preclinical research, these DOX-loaded micelles have been thoroughly examined for the delivery of numerous anticancer drugs.To overcome drug resistance and ensure the best drug delivery to the target region, polymeric nanomicelles (PNMs) employ a variety of techniques, including passive targeting, folate targeting, pH-sensitive targeting, and thermosensitive targeting. These techniques aid in increasing the therapeutic efficacy and targeted specificity of anticancer medications.[61] Due mostly to their poor water solubility, therapeutic presentations of anticancer drugs frequently experience limited absorption, poor bioavailability, and drug aggregation. [62-65] This problem is addressed by polymeric nanomicelles (PNMs), which greatly increase the water solubility of anticancer drugs by 10 to 5000 fold. PNMs can successfully entrap hydrophobic pharmaceuticals thanks to their inner core, which is made of a hydrophobic copolymer. Furthermore, the hydrophilic copolymer coating on the outside of PNMs minimises the interaction of pharmaceuticals with the aqueous medium, so ensuring their stability.In later research, were used a new class of "conjugates". With medications based on transition metals, such as cisplatin, DACHPt, and oxaliplatin, these conjugates can form stable complexes.By exchanging ligands with chloride ions in biological settings, these micelles release drugs.[70]

Graft copolymers were created and self-assembled into core-shell nanomicelles in one study. [71] these nanomicelles, 5-fluorouracil (5-FU) was added to the nanomicelles. These nanomicelles' structural deformation and drug release capabilities were examined. [72] In a different work, was created efficient for the of paclitaxel (PTX). The nanocarrier displayed a 100–230 nm size range and a high 98% encapsulation efficiency. In order to deliver the drug specifically to cancer cell tissues, the nanocarrier displayed aggregation [73-75] The dialysis method was also used to create brand-new copolymer micelle-based nanocarriers.[76]

Methotrexate (MTX) may function better as a medication if nanocarriers in the form of nanomicelles are created. [77] By acting as site-specific drug delivery vehicles, these nanocarriers may improve medication accumulation at diseased locations. [78] Studies on in vitro cytotoxicity, cellular absorption, and in vivo anticancer activity can support nanomicelles' capacity to react to variations in pH and temperature and validate their efficacy. [79] By adding target moieties into the architecture of the targeting nanomicelles, dynamic targeting can be achieved, maximising drug distribution while minimising side effects. Based on their specialised interactions with certain targets or by coupling with locally active signal proteins, [80] For instance, to specifically target tumour cells, paclitaxel-loaded phosphatidyl ethanolamine (PEG-PE) micelles were modified with MCF-7-selective phage fusion proteins. [81] When compared to normal cells, these targeted phage nanomicelles showed better tumour selectivity, which enhanced anticancer results in mice. [82] A number of target substances, including aptamers, peptides, and antibodies, have also been investigated for their potential to target nanomicelles. For instance, when used to treat pancreatic cancer, nanomicelles loaded with platinum medicines and coupled with antitissue factor antibodies (TF) showed 15 times more cellular absorption and anticancer effects than non-targeted micelles. In addition, doxorubicin (DOX), an anticancer medication, was produced for targeted administration in triple-negative breast cancer,[83-85] Folic acid-derived CDs have the fluorescence feature that makes them potential bioimaging tools for TNBC. These targeting techniques precision and potency of nanomicelles as DDS, enabling better therapeutic results and less off-target effects in a variety of cancer types.[86]

Conclusion

The advantages that nanomicelles provide make them desirable as medication carriers. They can avoid both static barriers like the reticuloendothelial system (RES) and dynamic obstacles like blood arteries and cell membranes thanks to their small size and distinctive structure. This lessens the possibility of off-target effects and enables effective drug delivery to the target region.Nanomicelles also have outstanding solubility and stability properties. Lipophilic pharmaceuticals can be encapsulated by the hydrophobic core of nanomicelles, improving their solubility and reducing drug aggregation. In the body, the drug payload is stabilised and protected by the hydrophilic shell of nanomicelles.Nanomicelles to improve targeting and controlled release when used as medication carriers. By adding ligands, surface changes can be used to accomplish active targeting.

References

1. Milovanovic, M., et al.: Nanoparticles in antiviral therapy. Antimicrobial Nanoarchitectonics, pp. 383–410 (2017)
2. Kataoka, K., et al.: Block copolymer micelles as vehicles for drug delivery. J. ontroll. Release. 24(1-3), 119–132 (1993)
3. Butkar, U. (2014). Synthesis of some (1-(2, 5-dichlorophenyl)-1H-pyrazol-4yl (2-hydroxyphenyl) methanone and 2-(1-(2, 5-dichlrophenyl)-1H-pyrazol-4yl) benzo (d) oxazole. International Journal of Informative & Futuristic Research (IJIFR), 1(12)
4. Nagayama, S., et al.: Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm. 342(1–2), 215–221 (2007)
5. Vega-Villa, K.R., et al.: Clinical toxicities of nanocarrier systems. Adv. Drug. Deliv. Rev. 60(8), 929–938 (2008)
6. Ning, Y.M., et al.: Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncol. (Williston Park). 21(12), 1503–1508 (2007)
7. Ogawara, K.I., et al.: Determinants for in vivo anti-tumour effects of PEG liposomal doxorubicin: importance of vascular permeability within tumours. Int. J. Pharm. 359(1-2), 234–240 (2008)
8. Maeda, H., et al.: Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review.J.ControlRelease. 65(1-2), 271–284 (2000)
9. Bertrand, N., et al.: Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2–25 (2014)
10. Hubbell, J.A., Chilkoti, A.: Nanomaterials for drug delivery. Science. 337(6092), 303–305 (2012)
11. Schroeder, A., et al.: Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer. 12(1), 39–50 (2012)
12. Cabral, H., et al.: Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6(12), 815 (2011)
13. Chauhan, V.P., et al.: Normalisation of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7(6), 383–388 (2012)
14. Trivedi, R., Kompella, U.B.: Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomed. 5(3), 485–505 (2010)
15. Determan, M.D., et al.: Drug release from pH-responsive thermo gelling pentablock copolymers. J. Biomed. Mater. Res. 81(2), 326–333 (2007)
16. Qiu, L., et al.: Reverse self-assemblies based on amphiphilic polyphosphazenes for encapsulation of water-soluble molecules. Nanotechnol. 18(47), 475602 (2007)
17. Melo, E.P., et al.: Reverse micelles and protein biotechnology. Biotechnol. Annu. Rev. 7, 87–129 (2001)
18. Torchilin, V.P.: Micellar nanocarrierrs: pharmaceutical perspectives. Pharm. Res. 24(1), 1 (2007)
19. Bourzac, K.: Nanotechnology: carrying drugs. Nature. 491(7425), 58–60 (2012)
20. Cholkar, K., et al.: Topical delivery of aqueous micellar resolving E1 analog (RX-10045). Int. J. Pharm. 498(1-2), 326–334 (2016)
21. Cholkar, K., et al.: Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl. Vis. SciTechnol. 4(3), 1–1 (2015)
22. Koo, O.M., et al.: Camptothecin in sterically stabilised phospholipid micelles: a novel nanomedicine. Nanomed. 1(1), 77–84 (2005)
23. Wiradharma, N., et al.: Self-assembled polymer nanostructures for delivery of anticancer therapeutics. Nano Today. 4(4), 302–317 (2009)
24. Adams, M.L., et al.: Amphiphilic block copolymers for drug delivery. J. Pharmaceut. Sci. 92(7), 1343–1355 (2003)

25. Lavasanifar, A., et al.: Poly (ethylene oxide)-block-poly (L-amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 54(2), 169–190 (2002)
26. Velagaleti, P.R., et al.: Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior and posterior segments of the eye. Drug Deliv. Technol. 10(4), 42–47 (2010)
27. Kabanov, A.V., et al.: Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Contr. Release. 82(2–3), 189–212 (2002)
28. Xu, W., et al.: Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J. Drug Deliv. 2013, 15 (2013). Article ID 340315.
29. Yokoyama, M., et al.: Block copolymers as drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 9(3-4), 213–248 (1992)
30. Hsu, C.H., et al.: Self-assembly behavior of A-B diblock and C-D random copolymer mixtures in the solution state through mediated hydrogen bonding. Langmuir. 24(15), 7727–7734 (2008)
31. Gao, W.P., et al.: Controlling vesicle formation via interpolymer hydrogen-bonding complexation between poly (ethylene oxide)-block- polybutadiene and poly (acrylic acid) in solution. Macromolecules. 39(14), 4894–4898 (2006)
32. Kuo, S.-W., et al.: Supramolecular micellization of diblock copolymer mixtures mediated by hydrogen bonding for the observation of separated coil and chain aggregation in common solvents. Macromol. Rapid Commun. 29(3), 229–233 (2008)
33. Yoncheva, K., et al.: Stabilized micelles as delivery vehicles for paclitaxel. Int. J. Pharm. 436(1-2), 258–264 (2012)
34. Lee, E.S., et al.: Poly (L-histidine)-PEG block copolymer micelles and pH-induced destabilisation. J. Contr. Release. 90(3), 363–374 (2003)
35. Bromberg, L., et al.: Polymeric micelles in oral chemotherapy. J. Contr. Release. 128(2), 99–112 (2008)
36. Lee, E.S., et al.: Polymeric micelle for tumour pH Land folate-mediated targeting. J. Contr. Release. 91(1–2), 103–113 (2003)
37. Tang, B.C., et al.: Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. U.S.A. 106(46), 19268–19273 (2009)
38. Smart, J.D., et al: The basics and underlying mechanisms of mucoadhesion. Adv. Drug Deliv. Rev. 57(11), 1556–1568 (2005)
39. Ponchel, G., et al.: Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34(2–3), 191–219 (1998)
40. Crater, J.S., et al.: Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol. Biosci. 10(12), 1473–1483 (2010)
41. Lin, H.M., et al.: Light-sensitive intelligent drug delivery systems of coumarin-modified mesoporous bioactive glass. Acta Biomater. 6(8), 3256–3263 (2010)
42. Sammalkorpi, M., et al.: Ionic surfactant aggregates in saline solutions: sodium dodecyl sulphate (SDS) in the presence of excess sodium chloride (NaCl) or calcium chloride (CaCl2). J. Phy. Chem. B. 113(17), 5863–5870(2009)
43. Alvarez-Lorenzo, C., et al.: Light-sensitive intelligent drug delivery systems. Photochem. Photobiol. 85(4), 848–860 (2009)
44. Kedar, U., et al.: Advances in polymeric micelles for drug delivery and tumour targeting. Nanomed. Nanotechnol. Biol. Med. 6(6), 714–729 (2010)
45. Chen, H., et al.: Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today. 16(7–8), 354–360 (2011)
46. Sant, V.P., et al.: Enhancement of oral bioavailability of poorly water- soluble drugs by poly (ethylene glycol)-block-poly (alkyl acrylate-co- methacrylic acid) self-assemblies. J. Contr. Release. 104(2), 289–300 (2005)
47. Xie, J., et al.: Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharma. Res. 22(12), 2079–2090 (2005)
48. Meng, F.T., et al.: W/O/W double emulsion technique using ethyl acetate as organic solvent: effects of its diffusion rate on the characteristics of microparticles. J. Contr. Release. 91(3), 407–416 (2003)
49. Kabanov, A.V., et al.: Micelles of amphiphilic block copolymers as vehicles for drug delivery. In: Amphiphilic Block Copolymers, pp. 347–376 (2000)
50. Cholkar, K., et al.: Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech. 16(3),610–622 (2015)

51. Cholkar, K., et al.: Optimization of dexamethasone mixed nanomicellar formulation. AAPS PharmSciTech. 15(6), 1454–1467 (2014)
52. Chiappetta, D.A., et al.: Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomater. 32(9), 2379–2387 (2011)
53. Savić, R., et al.: Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions. J. Drug Target. 14(6), 343–355 (2006)
54. Ahn, J., et al.: Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomater. 39, 23–30 (2015)
55. Trinh, H.M., et al.: Nanomicelles in diagnosis and drug delivery. In Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices, pp. 45-58. Elsevier (2017)
56. Wang, X.Q., Zhang, Q.: pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82(2), 219–229 (2012)
57. Wu, X.L., et al.: Tumour-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjugate Chem. 21(2), 208–213 (2010)
58. Kim, D., et al.: Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumour. Pharm. Res. 25(9), 2074–2082 (2008)
59. Bae, Y., et al.: Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumour permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjugate Chem. 16(1), 122–130 (2005)
60. Singh, R., Lillard, J.W. , Jr.: Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86(3), 215–223 (2009)
61. Bae, Y., Kataoka, K.: Intelligent polymeric micelles from functional poly (ethylene glycol)-poly (amino acid) block copolymers. Adv. Drug Deliv. Rev. 61(10), 768–784 (2009)
62. Rapoport, N.: Physical stimuli-responsive polymeric micelles for anti- cancer drug delivery. Prog. Polym. Sci. 32(8-9), 962–990 (2007)
63. Torchilin, V.: Tumour delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63(3), 131–135 (2011)
64. Kim, T.Y., et al.: Phase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Canc. Res. 10(11), 3708–3716 (2004)
65. Gong, J., et al.: Polymeric micelles drug delivery system in oncology. J. Contr. Rel. 159(3), 312–323 (2012)
66. Oerlemans, C., et al.: Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 27(12), 2569–2589 (2010)
67. Civiale, C., et al.: Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int. J. Pharm. 378(1–2), 177–186 (2009)
68. Patel, A., et al.: Ocular drug delivery systems: an overview. World J. Pharmacol. 2(2), 47–64 (2013)
69. Vadlapudi, A.D., Mitra, A.K.: Nanomicelles: an emerging platform for drug delivery to the eye. Ther. Deliv. 4(1), 1–3 (2013)
70. Fireman, S., et al.: A look at emerging delivery systems for topical drug products. Dermatol. Ther. 24(5), 477–88 (2011)
71. Lee, R.W., Shenoy, D.B., Sheel, R.: Micellar nanoparticles: applications for topical and passive transdermal drug delivery. In: Handbook of Non- invasive Drug Delivery Systems, pp. 37–58. Elsevier (2010)
72. Makhmalzade, B.S., Chavoshy, F.: Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders. J. Adv. Pharm. Technol. Res. 9(1), 2 (2018)
73. Javadzadeh, Y., Bahari, L.A.: Therapeutic nanostructures for dermal and transdermal drug delivery. In: Nano-and Microscale Drug Delivery Systems, pp. 131–146 (2017)
74. Soga, O.; van Nostrum, C.F.; Ramzi, A.; Visser, T.; Soulimani, F.; Frederik, P.M.; Bomans, P.H.H.; Hennink, W.E. Physicochemical Characterization of Degradable Thermosensitive Polymeric Micelles. Langmuir 2004, 20, 9388–9395.
75. Soga, O.; van Nostrum, C.F.; Hennink, W.E. Poly(N-(2-hydroxypropyl) Methacrylamide Mono/Di Lactate): A New Class of Biodegradable Polymers with Tuneable Thermosensitivity. Biomacromolecules 2004, 5, 818–821.
76. Chung, J.E.; Yokoyama, M.; Yamato, M.; Aoyagi, T.; Sakurai, Y.; Okano, T. Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate). J. Control. Release 1999, 62, 115–127.

77. Chen, W.; Su, L.; Zhang, P.; Li, C.; Zhang, D.; Wu, W.; Jiang, X. Thermo and pH dual-responsive drug-linked pseudo-polypeptide micelles with a comb-shaped polymer as a micellar exterior. Polym. Chem. 2017, 8, 6886–6894.
78. Ghamkhari, A.; Sarvari, R.; Ghorbani, M.; Hamishehkar, H. Novel thermoresponsive star-liked nanomicelles for targeting of anticancer agent. Eur. Polym. J. 2018, 107, 143–154.
79. Vitol, E.A.; Rozhkova, E.A.; Rose, V.; Stripe, B.D.; Young, N.R.; Cohen, E.E.W.; Leoni, L.; Novosad, V. Efficient Cisplatin Pro-Drug Delivery Visualized with Sub-100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles with a Living System. Adv. Mater. Interfaces 2014, 1, 1400182.
80. Fentahun Darge, H.; Yibru Hanurry, E.; Simegniew Birhan, Y.; Worku Mekonnen, T.; Tizazu Andrgie, A.; Chou, H.-Y.; Lai, J.-Y.; Tsai, H.-C. Multifunctional drug-loaded micelles encapsulated in thermo-sensitive hydrogel for in vivo local cancer treatment: Synergistic effects of anti-vascular and immuno-chemotherapy. Chem. Eng. J. 2021, 406, 126879.
81. Weissleder, R. A clearer vision for in vivo imaging. Nat. Biotechnol. 2001, 19, 316.
82. Lee, S.E.; Liu, G.L.; Kim, F.; Lee, L.P. Remote Optical Switch for Localized and Selective Control of Gene Interference. Nano Lett. 2009, 9, 562–570.
83. Yang, Y.; Liu, F.; Liu, X.; Xing, B. NIR light controlled photorelease of siRNA and its targeted intracellular delivery based on upconversion nanoparticles. Nanoscale 2013, 5, 231–238.
84. Lin, H.M.; Wang, W.K.; Hsiung, P.A.; Shyu, S.G. Light-sensitive intelligent drug delivery systems of coumarin-modified mesoporous bioactive glass. Acta Biomater. 2010, 6, 3256–3263.
85. Alvarez-Lorenzo, C.; Bromberg, L.; Concheiro, A. Light-sensitive Intelligent Drug Delivery Systems. Photochem. Photobiol. 2009, 85, 848–860.
86. Goodwin, A.P.; Mynar, J.L.; Ma, Y.; Fleming, G.R.; Fréchet, J.M.J. Synthetic Micelle Sensitive to IR Light via a Two-Photon Process. J. Am. Chem. Soc. 2005, 127, 9952–9953.